Hello, my name is Martin Jönsson, and I am the CEO of AlzeCure Pharma. I am here to give an update presentation on our company. The agenda we have today is to talk about AlzeCure Pharma with regard to what we are focusing on and our business model. We will also give an update on our two transformative deals that we did this summer, and that is with Eli Lilly and QuantumCell. Then we will also talk about our second Painless platform, which we now are having increasing focus on. Then we will talk about the strategy that we are having and the value drivers that we are working with going forward. If we begin with AlzeCure in brief, we are a company focusing on Alzheimer's and pain, and these are areas of huge unmet medical need. Only within the Alzheimer's field, we are expecting the number of patients to triple in the coming 30 years. We as a company, we are a spin-out of AstraZeneca. When AstraZeneca left the CNS and Alzheimer's space, AlzeCure was created. We have had funding from the Swedish Alzheimer's Foundation, which we still are working a lot with. We are based in Stockholm, Sweden, at Karolinska Institutet. We are working with platforms with small molecules that we create in-house, and we create first-in-class and best-in-class molecules. Lately, we have done two out-licensing and collaboration deals. We have Alzstatin, our first platform, where we are developing a therapy to prevent or to treat Alzheimer's disease. This is a platform that we have out-licensed to Eli Lilly. Then we have NeuroRestore. NeuroRestore is another Alzheimer's and CNS platform, where we are focusing on improving learning and memory capabilities, and also to treat depression. Here we have done an out-licensing deal with a Danish/U.S. biotech and pharma company, QuantumCell. Thirdly, we have a platform of pain assets, and we will go more into depth on those programs. As a company, we are listed at Nasdaq First North Premier Growth Market in Stockholm, Sweden. We have a market cap of about SEK 1.2 billion. We have a good cash position. This summer, we have received upfront payments of $22 million. We have done a right issue of SEK 30 million. We also have a grant from the European Innovation Council that we got last year. Our business model is that we are a research and development company. We are identifying targets, and then we are taking them through molecule development into clinical, and then to out-license. This is exactly what we have done this year. If we look at our pipeline of small molecule programs, we have NeuroRestore, which is a so-called Trk- PAM to improve BDNF and NGF signaling. Here we are focusing on Alzheimer's disease, but we have multiple additional indications, including depression and psychiatric disorders. Here we have been preparing for phase II in Alzheimer's disease, and this summer we have out-licensed this program to QuantumCell, and we will describe this deal later on. Additionally, our second Alzheimer's platform, Alzstatin. Here we are developing a gamma-secretase modulator to prevent or treat Alzheimer's disease. This platform has been out-licensed to Eli Lilly, and this we also did this summer. Additionally, we have Painless, where we have our pain platforms. Here we have ACD137, a TrkA-NAM blocking off NGF signaling. Here we are working on this program to get it prepared for phase I in osteoarthritis. Additionally, we have ACD440, which is a TRPV1 antagonist to treat neuropathic pain and also with orphan designation for a rare disorder called erythromelalgia. Here we have orphan designation from both EMA and FDA. We also have positive feedback from the FDA on a potential pivotal trial. Then to the deals that we lately have done, which is really validating the company and our business model. Here we have done this in our Alzheimer's program. So Alzstatin to prevent or treat Alzheimer's disease, Eli Lilly and Company has entered an agreement with us. Then on NeuroRestore, QuantumCell. In QuantumCell, it is to improve learning and memory capabilities and to treat mental disorders. Both of these deals, which have deal value on $3.2 billion, excluding royalties. These are out-licensing and collaboration deals. So here, AlzeCure Pharma will stay on in these programs and collaborate with Eli Lilly and QuantumCell. If we look at the agreement we have entered with Eli Lilly, deal value over $1 billion and an upfront of SEK 10 million. Here we have milestone payments in this setup, preclinical development, commercial, regulatory. Here we now have started the collaboration with Eli Lilly, working with tech transfer and starting up the program. What they have in license is a therapy to prevent that you build up plaque in the brain. How do we do that? We have been looking at how plaque is developed in the brain. This is based on that there are proteins, amyloid-beta 42, which are cleaved out and which then are coagulating up into bigger and bigger fragments, which are toxic and are creating plaque. What we are doing is that we are minimizing the creation of the toxic species, Aβ42. By that, we can decrease the creation of these toxic proteins and plaques. Additionally, we have last year also come up with data showing that it looks like that we also can affect plaque and the regression of plaque and plaque clearance. So here we are having a platform both decreasing the creation of plaque, but also hopefully that we can see later on that we also can reduce and clear existing plaque. Then we have the second deal, the one with QuantumCell on the program NeuroRestore. A deal value of $2.2 billion, which is the biggest ever in Swedish biotech history. Here we have an upfront of SEK 12 million. Also here we have additional royalties, which are up to double digits. Here we also have different milestone payments from preclinical development, regulatory, and commercial. Also here we have started the collaboration with QuantumCell. QuantumCell is an unknown company for many people. QuantumCell has been created with the funding and the initiative from Novo Holdings, from Lundbeckfonden, from First Spark Ventures, and Forbion, major life science investors. Additionally, in their board of directors, they have the former global R&D head from Pfizer, Mikael Dolsten. He said no to joining Novo's board of directors and yes to join QuantumCell, and we think this is quite a statement. We have been working with QuantumCell for a long time with regard to the due diligence. We have been very impressed with them and feel very comfortable with working with them now on these programs. What they have in license is the NeuroRestore program, where we are focusing on the neurotrophins BDNF and NGF, which are key when it comes to brain health, learning and memory capabilities, but also to treat mental disorders, depression. Here it is about that we know that individuals who are low on BDNF, they also have a more rapid disease progression in Alzheimer's and neurodegenerative diseases. What we have created are molecules which are increasing the signaling of BDNF and NGF in the system. We have preclinical data showing that we can improve learning and memory capabilities, also positive data from depression models. We also have positive data when it comes to potential disease-modifying abilities like neural proliferation, neuroprotection of the neurons, neurite outgrowth, improved synaptic plasticity, increasing mitochondrial function, and also anti-inflammatory effects. All of these factors, as we see it, can also lead to that we can potentially see a disease-modifying effect. Then we have our pain programs, which we have in the platform Painless. Here we have two, one where we are focusing on osteoarthritis. Here we have more than 300 million patients. Then we also have neuropathic pain. In neuropathic pain, there are today more than 600 million individuals suffering from neuropathic pain. Both these areas, we see a growing patient population. In osteoarthritis, we see an aging population driving the number of patients, but also overweight problems, which are leading to additional pain problems and osteoarthritis. If we begin to look at our program for osteoarthritis, ACD137, which is the so-called TrkA-NAM, blocking off NGF signaling. This is a concept validated by the NGF antibodies, which have been in clinical trials up to phase III and shown a very good analgesic effect. But these programs showed side effects which led to that the regulatory bodies like the FDA didn't approve these programs. What we have done are developing small molecules which are blocking off the NGF signaling. We have compared them with anti-NGF antibodies, tanezumab, and we have shown that we have at least as good as an effect as the antibody, and also that we have a potential protective effect. We are developing this program as a tablet medication. This comes to also our Alzheimer's programs. When it comes to this program, TrkA-NAM ACD137, this is an area where there is a very big interest within the pain space, including from big pharma companies. We have developed molecules which are very potent and also selective. Here we are preparing this program for a clinical trial, phase I. Already today, this target and mechanism is validated by Asahi Kasei, who have had successful phase II-A in osteoarthritis. They are now also driving an additional trial, which could have a readout this year in 2026. Then we have our second pain program, and that is ACD440, which is a TRPV1 antagonist for neuropathic pain. This is a program that we have in-license, which originates from Big Pharma. We have reformulated this program into a gel. We have driven clinical trials and had positive results. Our latest results were in peripheral neuropathic pain, where we treated chronic patients. Here we showed that we had 50% analgesic effect in patients with temperature-induced neuropathic pain. We did not see any side effects, and we also saw that it was very well tolerated. This is now a program that we are driving forward. Here we have identified an orphan indication called erythromelalgia. It is a pain disorder where individuals are developing very intense pain, and this is hitting both children and adults, and they can have this very intense pain for days. Today, there is no effective treatment for erythromelalgia. Therefore, based on the science that we have presented, both the FDA and EMA have given us orphan designation for erythromelalgia. FDA has also given us positive feedback on a potential pivotal trial in erythromelalgia, and this is a program that we are working on driving forward. If we look at our strategy and value drivers going forward, what are we focusing on? First of all, we have a focus on really starting and having great collaboration with both Eli Lilly and QuantumCell on our Alzheimer's and CNS program. Additionally, we are driving Painless TrkA-NAM for osteoarthritis forward, preparing it for phase I. Then we also have Painless ACD440 for neuropathic pain and also for erythromelalgia. This program we are also driving forward, and here we are working both with regard to regulatory questions and clinical trials. Additionally, focusing on business development to out-license this program. Business development is something that we have a high focus on based on our existing programs. It takes time to build a relationship and prepare out-licensing, and this is also what we are doing. To summarize today's presentation, key investment highlights with regard to AlzeCure. We have, this year, done two major out-licensing agreements, truly validating our company. This with deals which have led to deal values of $3.2 billion, excluding royalty on future sales. Additionally, we have received $22 million in upfront and SEK 30 million in a rights issue. Additionally, we have, for the future, several value drivers and increased focus on our pain projects, ACD137 and ACD440, where we are focusing and working on getting these ready for the next and also to out-license. Additionally, we have programs within areas where you see a significant unmet medical need, and also that we truly have a proven business model where we have shown that we as a company, we can identify targets, we can develop molecules, we can take them through preclinical work, clinical, and then to out-license them, which is validating our business model. To learn more about AlzeCure, please visit our website for the company or reach out to us and we are happy to have additional discussion on our company. Thank you for your attention and have a great day. Thank you.